those four, only one is a pharmaceutical company where are the customer testimonials from pfizer, novartisb. why aren't they on the customer testimonials page. we talked to a very comprehensive set of customers there's always some user in some company. you know, you may have, you know, some sort of positive experience with a technology there are some one off use cases where people, they pay $2 million for a machine to try to get some use out of this some sort of experiment they can run. but let's just step back for a moment let me make one very important high level observation about this company if you're in the stock, there's basically one question you need to be asking yourself. you know, this is a company that trades at 20 times sales it's valued like a growth stock. yesterday morning before we published our report, it was trading 27 times sales basically flat over the last two years yet it has a growth stock multiple they started selling this product in 2016. they placed 92 of the systems, 92 over five years, they say they have a $22 billion tim the elephant in the room is 22 bil billi

costs £2000 per dose but the health service has negotiated an undisclosed discount with its makers, novartistrokes are one of the most common causes of death and ill—health in the uk, and high cholesterol is a big risk factor. a healthy diet and exercise can help keep cholesterol down. but some people need medication, too. statins — a relatively cheap treatment, work for many, but not all. now patients in england and wales could be offered a new drug called inclisiran. it's a cholesterol busting injection given twice a year, and could help patients for whom statins don't do enough. people like zena foster from newcastle. i've worked through four statins. i'm on my fourth statin now. so this, i guess the thing to say about heart disease is that it is relentless. there is no cure and ijust aim to slow the progress. i think, importantly, it gives hope. and hope is a precious commodity when you have heart disease. more than two in five people in england have high cholesterol and 6.5 million adults are currently taking cholesterol—lowering drugs such as statins. nhs england says the new treatment

attention to in particular those that money is going to be flowing into as interest rates start to rise novartis, exxonmobil, verizon. these are particular companies that you can own for a long time and you can also have, you know -- you are going to see these particular companies gather money as we move into the latter part of the year. >> we should emphasize, since you are looking at dividends, yes there are tech names in the mix that you mentioned but there is also a exxon. there is a 6% dividend yield there. are you afraid of losing principle or not -- not principle, but you know what i am sake. how do you think the stock purchases? could it continue to run up with oil prices but are you concerned about what lies on the other side of that >> companies like exxon protect their dividend at all costs. i am not worried about the dividend i think what investors needs to be paying attention to is the cash flow of the companies, the growth of the companies. oil prices are probably going to stay high, particularly if we have inflation i think that particular name is safe for a while >> jamie, it's d

companies like novartis have paired back on that a little bit.opportunity there and consumer staples. one sector that has been left behind so far since the big global rebound after the pandemic. areas such as financials have had a big bounce on the back of reopening economies, particularly this year on the back of november last year. even though they are coming off a very low base, there may not be much more from there. tom: anything you heard from jay powell that changes your views on u.s. equities. we are going to get less support from the fed going forward? >> ultimately. he also said they would do what they could to support the u.s. economy in reopening and what we have to think about is while this is still ongoing, equity markets could tonight to rally and with that support, i think what they really said is they talked about tapering. it is not as extreme as some might have thought and what we have to try and prepare ourselves for as evaluations increase, then return expectations like perhaps going forward, the u.s. has a strong -- since las

£2,000 per dose, but the health service has negotiated an undisclosed discount with its makers, novartisisk factor. a healthy diet and exercise can help keep cholesterol down. but some people need medication, too. statins — a relatively cheap treatment, work for many, but not all. now patients in england and wales could be offered a new drug called inclisiran. it's a cholesterol—busting injection given twice a year, and could help patients for whom statins don't do enough. people like zena foster from newcastle. i've worked through four statins. i'm on my fourth statin now. so this, i guess the thing to say about heart disease is that it is relentless. there is no cure, and ijust aim to slow the progress. i think, importantly, it gives hope. and hope is a precious commodity when you have heart disease. more than two in five people in england have high cholesterol and 6.5 million adults are currently taking cholesterol—lowering drugs such as statins. nhs england says the new treatment, inclisiran, could save around 30,000 lives within a decade. there is a huge unmet need. high cholesterol

but deutsche bank becoming negative on novartis. we'll expect to see that stock dropping add well.t's joe easton. you mentioned in the program that it's possible that the european open is negative that some of those fierce start to -- fears start to ease. but it is still a more weak session. i mean, is this something that that continue? or do you still expect that perhaps some of those fears as trading goes underway? mark: it's a great question, dan irks, you can see futures have dipped a little bit lore. european stock fedders want to push this sentiment further. it comes down with how the hong kong stock market closes got another hour of trading minus 4.22% will put it as the worst session since last year. it's a little bit oh off the low as it was down for man 4%. but people are concerned about hong kong. but the extra backdrop here is that on the other side of the world not in europe but on the u.s. we have seen the s&p 500 trading really, really badly. we're seeing futures very heavy there this morning. the sentment be quite lower in europe. dani: it's been like 40 days since